Chemistry:D-Phenylalanine
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Deprenon, Sabiben, Sabiden |
| Other names | D-(+)-Phenylalanine; (R)-(+)-Phenylalanine; (R)-Phenylalanine; D-β-Phenylalanine; DPA; D-Phe |
| Routes of administration | By mouth |
| Drug class | Antidepressants; Enkephalinase inhibitors |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C9H11NO2 |
| Molar mass | 165.192 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
D-Phenylalanine (DPA, D-Phe), sold under the brand names Deprenon, Sabiben, and Sabiden, is an enantiomer of phenylalanine which is described as an antidepressant and is marketed as a prescription drug for medical use in Argentina.[1][2] The medication has been marketed since at least the 1970s[3] and continued to be available by the 2000s.[1]
D-Phenylalanine has been found to act as an enkephalinase inhibitor, an inhibitor of enkephalinase enzymes that break down endogenous opioid peptides called enkephalins.[4][5] It has been found to produce anti-inflammatory, analgesic, and anti-craving effects in animal studies.[4][6][7][8]
See also
References
- ↑ 1.0 1.1 Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 825. ISBN 978-3-88763-075-1. https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA825. Retrieved 23 July 2024.
- ↑ Negwer, M. (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey). Akademie Verlag. p. 323. ISBN 978-3-05-500156-7. https://books.google.com/books?id=1ghtAAAAMAAJ. Retrieved 23 July 2024. "D-Phenylalanine (●) D-α-Amino-β-phenylpropionic acid = (R)-α-Aminobenzenepropanoic acid S Deprenon "Promeco", D-Phenylalanine, Sabiden U Antidepressant"
- ↑ Unlisted Drugs. Unlisted Drugs Committee of the Pharmaceutical Section, Science-Technology Group, Special Libraries Association. 1979. https://books.google.com/books?id=WCZRAQAAIAAJ. Retrieved 23 July 2024.
- ↑ 4.0 4.1 "Neutral amino acid therapy for the management of chronic pain". Cranio 4 (2): 157–163. April 1986. doi:10.1080/08869634.1986.11678141. PMID 3519793.
- ↑ "Enkephalinase inhibitors: potential agents for the management of pain". Curr Drug Targets 9 (10): 887–894. October 2008. doi:10.2174/138945008785909356. PMID 18855623.
- ↑ "Alcohol and opioid peptides: neuropharmacological rationale for physical craving of alcohol". Am J Drug Alcohol Abuse 13 (3): 365–372. 1987. doi:10.3109/00952998709001520. PMID 2825513.
- ↑ "Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS)". J Neurol Sci 411. April 2020. doi:10.1016/j.jns.2020.116733. PMID 32088516.
- ↑ "Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity". Curr Pharm Des 22 (38): 5837–5854. 2016. doi:10.2174/1381612822666160719111346. PMID 27510492.
 |  |
